Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules

[1]  C. Ling,et al.  Effect of respiratory gating on quantifying PET images of lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  H. Tonami,et al.  Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  K. S. Lee,et al.  Localized form of bronchioloalveolar carcinoma: FDG PET findings. , 1998, AJR. American journal of roentgenology.

[4]  E. Hirschowitz,et al.  Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies , 2002, Annals of nuclear medicine.

[5]  M. Phelps,et al.  FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  [2002 Standards, Options and Recommendations for the use of [18F]-FDG (PET-FDG) in cancerology]. , 2003, Bulletin du cancer.

[7]  S. Vallabhajosula,et al.  Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Abass Alavi,et al.  Positron emission tomography imaging in nonmalignant thoracic disorders. , 2002, Seminars in nuclear medicine.

[9]  I. Virgolini,et al.  Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? , 1997, European journal of clinical investigation.

[10]  A. Alavi,et al.  Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  W. Mcbride,et al.  Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. , 1996, Journal of medicinal chemistry.

[12]  R L Wahl,et al.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  P C Goodman,et al.  Evaluation of primary pulmonary carcinoid tumors using FDG PET. , 1998, AJR. American journal of roentgenology.

[14]  J. Machac,et al.  Peptide and antibody imaging in lung cancer. , 2002, Seminars in nuclear medicine.

[15]  K. Berbaum,et al.  The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. , 2004, Chest.

[16]  R. Lecomte,et al.  Respiratory gating for 3-dimensional PET of the thorax: feasibility and initial results. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  P. Bourguet.  [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in bronchopulmonary and pleural cancers]. , 2003, Bulletin du cancer.

[18]  D. Ost,et al.  Clinical practice. The solitary pulmonary nodule. , 2003, The New England journal of medicine.

[19]  P. Valent,et al.  Tc-p829 99m of a Novel Tumor Tracer, Binding in Vivo Somatostatin Receptor Subtype Specificity and Updated Version Citing Articles E-mail Alerts Somatostatin Receptor Subtype Specificity and in Vivo Binding of a Novel Tumor Tracer, 99mtc-p8291 , 2013 .

[20]  J. Blum,et al.  Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. , 2002, Current pharmaceutical design.

[21]  R Iwata,et al.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  W. Webb.  Radiologic evaluation of the solitary pulmonary nodule. , 1990, AJR. American journal of roentgenology.

[23]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  D. Ost,et al.  Solitary Pulmonary Nodule , 2005 .

[25]  J. Blum,et al.  The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. , 1999, Chest.

[26]  J. Blum,et al.  A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. , 2000, Chest.

[27]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[28]  Ella A Kazerooni,et al.  The solitary pulmonary nodule. , 2003, Chest.

[29]  Y. Yamaji,et al.  Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. , 1994, Life sciences.

[30]  K. O'Byrne,et al.  Somatostatin and the lung. , 1993, Lung cancer.